UPL Announces Collaboration with Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia
UPL Ltd., a global provider of sustainable agriculture solutions, today announced that its subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma Co., Ltd. for exclusive access to Flupyrimin for rice in Southeast Asia.
Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound.
In addition to this latest arrangement, in 2018 UPL’s subsidiary and Meiji entered into an exclusive licensing agreement for UPL to commercialize formulations of Flupyrimin for applications in rice in India. Furthermore, in 2020, the two companies signed a long-term global commercial exclusive agreement, excluding Japan, South Korea and Taiwan and non-exclusive in China, to use Flupyrimin in seed treatment and in-furrow applications.
Flupyrimin, discovered by Meiji, is a patented active ingredient and the only AI in the new mode of action subgroup, Pyridylidenes, defined by IRAC in 2021. It is a novel insecticide with unique biological properties that, among other benefits, is effective against major rice pests, such as brown plant hopper and rice stem borer, including those populations resistant to existing insecticides.
Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.
“We are pleased to expand our relationship with Meiji regarding Flupyrimin in this mutually beneficial collaboration to provide growers in Southeast Asia access to this important AI. Our OpenAgTM Purpose opens the door to developing and expanding key relationships that create sustainable growth for all and ensure farmer resilience,” said Jai Shroff, CEO of UPL. “Meiji is an important partner to UPL, and we look forward to continuing our collaboration, creating a win, win.”
“The UPL agreement is a significant step forward towards providing growers with differentiated solutions that address their challenges in the field. We are excited to continue to strengthen our relationship with UPL to deliver this innovative and effective AI to farmers in Southeast Asia,” said Daikichiro Kobayashi, President and Representative Director
TCS a Leader and Star Performer in Financial Crime and Compliance Operations: Everest Group
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been named a Leader and Star Performer in the Everest Group PEAK Matrix® for Financial Crime and Compliance (FCC) Operations.
In an assessment of 23 FCC operations service providers, TCS was placed highest for its market impact. Additionally, it was named a Star Performer for having top quartile year-on-year improvement in its scores. According to the report, TCS has developed strong capabilities in FCC operations with continued initiatives to enhance domain expertise as well as sharpen its technology offerings. The report cites TCS’ investments in bolstering offerings with the inclusion of platform-based solutions and digital levers like blockchain and cognitive automation, and to strengthen domain expertise with the hiring of SMEs and creation of a dedicated Centre of Excellence for FCC processes, as key strengths.
The report goes on to say that TCS has leveraged its talent pool to create frameworks, such as the Enterprise Regulatory Compliance Management Framework that offer end-to-end structured approaches to streamline compliance activities. It talks about TCS’ onshore and nearshore delivery model that aligns with the market demand. The report also recognizes TCS’ focus on expanding its FCC portfolio, with the company making inroads in regions such as Latin America and Continental Europe.
“Constantly changing risk landscapes, growing financial crimes and rising regulatory liabilities call for a more cohesive and comprehensive FCC mechanism. Today, an increasing number of banks and financial services firms are harnessing innovative technologies like AI and machine learning to build and maintain a robust defense against financial crime,” said K Krithivasan, Business Group Head, Banking, Financial Services, and Insurance, TCS. “This recognition from an independent third-party research firm is a reflection of our vision, capabilities, comprehensive portfolio of solutions, and the resultant market success.”
TCS has extensive experience partnering with some of the world’s largest banks, and has built unparalleled expertise in financial crime and compliance services across KYC (risk profiling, due diligence, screening, client outreach, off-boarding), AML (transaction monitoring, sanctions screening, trade AML) and anti-fraud operations (cybercrime). TCS’ comprehensive set of services in this domain include consulting, analytics, transformation and technology solutions, platform solutions, and change management services.
TCS works with over 15 of the top tier global banks, including the top three banking and financial services providers, a leading European multinational bank, a large global bank, and a fortune 500 European financial services provider.
“With the pandemic impacting agent availability, exposing internal vulnerabilities, and pushing the demand for digital, financial institutions are looking at third-party support for more than just handling the volumes. There is openness toward leveraging partnerships to explore more end-to-end engagements that include consulting, operations, and technology,” said Robin Jain, Practice Director, Everest Group. “TCS’ continuous investments to enhance its FCC capabilities with a focus on talent and technology backed by its market success are steps in the right direction to become a one-stop solution for all things FCC.”'
Infosys Announces Strategic Collaboration with Britvic to Accelerate their Digital Strategy
Infosys the global leader in next-generation digital services and consulting, today announced that it has been selected by Britvic, one of the leading branded soft drinks businesses in Europe, as a strategic end-to-end partner to help them deliver their strategic transformation roadmap and operations, across Applications, Cloud Infrastructure, Service Management and End User Computing.
As Britvic’s strategic partner, Infosys will provide end-to-end IT services and deliver a technology-driven approach to fulfill Britvic’s business goals and strategic digital transformation roadmap. Infosys will also simplify and streamline its cloud infrastructure and operations leveraging Infosys Cobalt while improving service delivery through analytics, automation and process maturity.
G E Shipping contracts to sell its old Midsize Gas Carrier (1996 Built) “Jag Vayu”
The Great Eastern Shipping Company Limited (G E Shipping) has contracted to sell its 1996 built Midsize Gas Carrier, Jag Vayu (1996 Built) of about 36,567 cbm. The vessel will be delivered to the new buyers in H1 FY 2021-22.
Including this vessel, the Company’s current fleet stands at 46 vessels, comprising 33 tankers (9 crude carriers, 18 product tankers, 6 LPG carrier) and 13 dry bulk carriers with an average age of 12.02 years aggregating 3.66 mn dwt. The company has previously contracted to buy a 2013 built Japanese Supramax Bulk Carrier which is expected to be delivered in Q1 FY 2021-22.
Dr. Reddy's Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Dr. Reddy’s Laboratories Ltd today announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (“Lilly”) for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company’s existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.